Autoimmune Hepatitis Cohort in China
Launched by SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE · Mar 14, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The Autoimmune Hepatitis Cohort in China is a clinical trial that aims to learn more about autoimmune hepatitis (AIH), a condition where the body's immune system attacks the liver. Researchers want to understand the symptoms that patients experience, how the disease progresses over time, and how effective and safe various treatment options are in everyday life. This study is currently recruiting participants aged 14 and older who have been diagnosed with AIH based on specific medical criteria.
To join the trial, participants need to have certain health information available from their initial diagnosis, and they must agree to take part in the study. However, individuals with specific other liver diseases or active infections, as well as those with certain cancers before their AIH diagnosis, will not be eligible. Participants can expect to contribute valuable information that may help improve the understanding and treatment of autoimmune hepatitis in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age ≥ 14 years
- • Probable or definite diagnosis of autoimmune hepatitis according to the International Autoimmune Hepatitis Study Group criteria
- • Availability of all following essential parameters at the initial diagnosis of AIH: including alanine transaminase, aspartate aminotransferase, total bilirubin, alkaline phosphatase, immunoglobulin G, and platelet count
- • Provide informed consent
- Exclusion Criteria:
- • Have a concomitant diagnosis of primary biliary sclerosis, primary sclerosing cholangitis, immunoglobulin G 4-related cholangitis
- • Have an active infection with hepatitis B virus, hepatitis C virus, hepatitis delta virus, HIV, cytomegalovirus, or Epstein-Barr virus
- • Have a concomitant diagnosis of hepatocellular carcinoma or other malignant diseases before the diagnosis of AIH
- • Considered ineligible to the enrollment in the clinical study by the researcher
About Shanghai Jiao Tong University School Of Medicine
Shanghai Jiao Tong University School of Medicine is a leading academic institution in China, renowned for its commitment to advancing medical research and education. As a prominent clinical trial sponsor, the school leverages its extensive expertise in biomedical sciences and innovative healthcare solutions to conduct rigorous clinical studies aimed at improving patient outcomes. With a focus on collaboration and translational research, the institution fosters partnerships with healthcare providers, industry leaders, and regulatory bodies to ensure the highest standards of scientific integrity and ethical conduct in clinical trials. Through its research initiatives, Shanghai Jiao Tong University School of Medicine strives to contribute significantly to the global medical community and enhance the quality of healthcare delivery.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Shanghai, Shanghai, China
Patients applied
Trial Officials
Xiong Ma, MD,PHD
Study Chair
Renji Hospital, School of Medicine, Shanghai Jiao Tong University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials